Furthermore, PARPi administration to BRCA1/2 mutant cells blocks prostate cancer growth, however, several markers of homologous recombination (HR) signaling are activated, leading to modest clinical outcome [51,52]. The gene discussed is BRCA1; the disease is prostate carcinoma.